Scoop has an Ethical Paywall
Work smarter with a Pro licence Learn More

Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search

 

Appointment of Duncan Mackintosh to lead NZ operations

Leading Australian life science venture firm announces appointment of Duncan Mackintosh to lead New Zealand operations


Melbourne, Australia and Auckland, New Zealand - July 26, 2016 – Brandon Capital Partners, one of Australia’s leading life science venture capital firms, today announced the expansion of its operations into New Zealand. The firm also announced that Duncan Mackintosh, a leader in technology commercialisation, has been appointed as Investment Manager and will lead New Zealand operations.

Brandon Capital Partners manages the Medical Research Commercialisation Fund (MRCF), a unique investment collaboration between major Australian superannuation funds and more than 50 of Australia’s leading medical research institutes and research hospitals. The MRCF was established to provide dedicated investment funding and expertise to support the development of very early stage research innovations. Since 2007, the MRCF has supported the development of 27 start-up companies developing technologies originating from members, with some notable successes, such as Spinifex Pharmaceuticals which was acquired by Novartis for US$725 million in 2015, and Fibrotech Therapeutics, which was acquired by Shire for $557 million (USD) in 2014.

In February 2016 Science and Innovation Minister Steven Joyce announced that New Zealand had joined Australia’s Medical Research Commercialisation Fund (MRCF), enabling New Zealand research organisations to become members of the fund and seek investment support for their emerging technologies from the third MRCF fund, an AU$200 million fund.

Advertisement - scroll to continue reading

Are you getting our free newsletter?

Subscribe to Scoop’s 'The Catch Up' our free weekly newsletter sent to your inbox every Monday with stories from across our network.

“Internationally, New Zealand ranks very highly in terms of its medical innovations and we are therefore excited to be expanding the MRCF to include New Zealand members. At $200M, our latest fund has the capacity to support the best research opportunities from across New Zealand and Australasia, from discovery to clinical development and commercialisation,” said Dr. Chris Nave, Managing Director of Brandon Capital Partners and Principal Executive of the MRCF.

“The expansion of MRCF’s membership network increases the opportunity for collaboration, capability sharing and knowledge aggregation. With key international linkages, including our newly established US office in the San Francisco Bay Area, the MRCF is providing access to key resources which overcome some of the key factors impeding the successful commercialisation of research discoveries in Australia and New Zealand. Building a presence in New Zealand is a key part of our goal to becoming a significant international life sciences fund. We’re delighted to have secured someone with Duncan’s extensive industry networks and strong record of achievement in the life science sector, to lead our NZ activities.”

Duncan Mackintosh has specialised in the development and commercialisation of life sciences and technology for the past 15 years, with his most recent role as Chief Executive of WaikatoLink, the commercial arm of the University of Waikato. He has co-founded a number of companies including Ligar Polymers LP, PA Therapeutics LLC, Aldera Animal Health, and Novatein which was later incorporated into Aduro Biopolymers. He was also a Co-Founder and founding Investment Committee Member of KiwiNet, a research commercialisation consortium. He holds a BVSc in Veterinary Science from Massey University and is a graduate of Lincoln University’s Kellogg Rural Leadership Programme.

Mackintosh says, “We have a very vibrant bio sector here in New Zealand with some first class life sciences researchers and research, which we’re looking forward to supporting. The MRCF funding helps promising technologies bridge the current market failure, the so called ‘Valley of Death’, enabling them to progress beyond grant funding to a point where they have achieved clinical or prototype proof of concept and/or market validation.”

Mackintosh says a priority is for New Zealand’s research organisations to sign up to gain access to the MRCF. “Member Institutes can then identify opportunities within their institute and bring them forward to the Investment Review committee.”

Early-stage opportunities can receive up to $3 million (AUD) to support preclinical development, with those successfully progressing through this stage able to receive a further $17 million (AUD) in investment support.

ENDS

© Scoop Media

Advertisement - scroll to continue reading
 
 
 
Business Headlines | Sci-Tech Headlines

 
GenPro: General Practices Begin Issuing Clause 14 Notices

GenPro has been copied into a rising number of Clause 14 notices issued since the NZNO lodged its Primary Practice Pay Equity Claim against General Practice employers in December 2023.More

SPADA: Screen Industry Unites For Streaming Platform Regulation & Intellectual Property Protections

In an unprecedented international collaboration, representatives of screen producing organisations from around the world have released a joint statement.More

 
 
 
 
 
 
 
 
 
 
 
 

Join Our Free Newsletter

Subscribe to Scoop’s 'The Catch Up' our free weekly newsletter sent to your inbox every Monday with stories from across our network.